Reirradiation of locally recurrent rectal cancer: A systematic review  by Guren, Marianne Grønlie et al.
Radiotherapy and Oncology 113 (2014) 151–157Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comSystematic ReviewReirradiation of locally recurrent rectal cancer: A systematic reviewhttp://dx.doi.org/10.1016/j.radonc.2014.11.021
0167-8140/ 2014 Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author at: Department of Oncology, Oslo University Hospital,
Ullevaal, P.O. Box 4956, Nydalen, NO-0424 Oslo, Norway.
E-mail address: Marianne.gronlie.guren@ous-hf.no (M.G. Guren).Marianne Grønlie Guren a,b,⇑, Christine Undseth a, Bernt Louni Rekstad c, Morten Brændengen a,
Svein Dueland a, Karen-Lise Garm Spindler d, Rob Glynne-Jones e, Kjell Magne Tveit a,b,f
aDepartment of Oncology; bK.G.Jebsen Colorectal Cancer Research Centre; cDepartment of Medical Physics, Oslo University Hospital, Norway; dDepartment of Oncology,
Aarhus University Hospital, Denmark; eCentre for Cancer Treatment, Mount Vernon Hospital, Northwood, UK; fUniversity of Oslo, Norway
a r t i c l e i n f oArticle history:
Received 3 July 2014
Received in revised form 10 October 2014
Accepted 15 November 2014
Available online 26 November 2014
Keywords:
Radiotherapy
Retreatment
Rectal cancer
Recurrence
Systematic reviewa b s t r a c t
Background: Many patients with rectal cancer receive radiotherapy as a component of primary multim-
odality treatment. Although local recurrence is infrequent, reirradiation may be needed to improve
resectability and outcomes. This systematic review investigated the effects of reirradiation in terms of
feasibility, toxicity, and long-term outcomes. Methods: A Medline, Embase and Cochrane search resulted
in 353 titles/abstracts. Ten publications describing seven prospective or retrospective studies were
included, presenting results of 375 patients reirradiated for rectal cancer. Results:Median initial radiation
dose was 50.4 Gy, median 8–30 months before reirradiation. Reirradiation was mostly administered
using hyperfractionated (1.2–1.5 Gy twice-daily) or 1.8 Gy once-daily chemoradiotherapy. Median total
dose was 30–40 Gy to the gross tumour volume with 2–4 cm margins. Median survival was 39–
60 months in resected patients and 12–16 months in palliative patients. Good symptomatic relief was
reported in 82–100%. Acute toxicity with diarrhoea was reported in 9–20%, late toxicity was insufﬁciently
reported. Conclusions: Reirradiation of rectal cancer to limited volumes is feasible. When curative resec-
tion is possible, the goal is radical resection and long-term survival, and hyperfractionated chemoradio-
therapy should be preferred to limit late toxicity. Reirradiation yielded good symptomatic relief in
palliative treatment.
 2014 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 151–157 This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Rectal cancer is a common disease, with an age-standardised
incidence rate of 17.3 per 100,000 person-years for colorectal
cancer world-wide [1]. Improved surgery with total mesorectal
excision [2] and increased use of preoperative radiotherapy (RT)
and chemoradiotherapy (CRT) have led to decreased recurrence
rates [3–7]. Population-based studies have demonstrated
increased survival of patients with rectal cancer [8,9]. Local recur-
rence of rectal cancer can be a devastating condition, because of
morbidity with intractable pain, pelvic infection, and obstruction,
with large impact on health-related quality of life (HRQOL) [10].
Although local recurrence rates have decreased, an increasing
proportion of patients with local recurrence have previously
received high-dose pelvic radiotherapy as part of the primary
multimodality treatment, either as preoperative short-course
radiotherapy (5  5 Gy) or as chemoradiotherapy to 45–50 Gy
(1.8–2.0 Gy/fraction). Curative resection of the local recurrence is
the most important factor for survival [11]. Reirradiation of previ-
ously irradiated patients may increase the rate of radical resection
(R0) and may also provide symptom palliation for inoperabletumours [12]. It is therefore important to determine the safety
and beneﬁts of reirradiation in patients with local recurrence.
In terms of optimising radiotherapy, the tumour should receive
a high total dose while sparing the surrounding normal tissue to
avoid toxicity. Reirradiation is challenging, because the surround-
ing normal tissues may have already received doses near the
organ- or endpoint-speciﬁc tolerance dose during the primary
treatment. Robust clinical data on long-term normal tissue recov-
ery and radiation tolerance doses are sparse. Therefore, radiation
oncologists have been wary of reirradiation in locally recurrent
rectal cancer, due to the fear of serious adverse late effects in nor-
mal tissue, particularly of the small intestine and bladder. How-
ever, there is increasing evidence in clinical studies that
reirradiation is tolerable and yields good results for different
tumour locations [13]. The potential morbidity caused by retreat-
ment should be weighed against the expected beneﬁts in terms
of achieving R0 surgery and long-term survival. If potentially cura-
tive treatment is envisaged, the expectation of long survival should
drive treatment planning with conformal doses, and hyperfraction-
ation should be considered for radiobiological reasons to reduce
the risk of late effects [14].
The aim of this systematic review was to investigate and
evaluate the efﬁcacy and safety in published studies describing
152 Reirradiation of rectal recurrencethe feasibility, outcomes, and toxicity of reirradiation of previously
irradiated locally recurrent rectal cancer. The main focus is on
external beam reirradiation, all fractionation regimens, with or
without concurrent chemotherapy; reirradiation combined with
other radiotherapy modalities is only brieﬂy discussed.Methods
This systematic review was based on a research protocol
describing the aims and methods. The review is reported according
to the guidelines in the PRISMA statement [15].Search strategy
A combined search was performed in the Medline, Embase, and
Cochrane databases, through December 2012, with updated search
August 2013. The search strategy included terms such as (colorectal
or rectal or rectum) and (neoplasms or cancer or tumour) and (reir-
radiation), with no limitations for year of publication. No reviews
of this topic were found in the Cochrane database. The titles/
abstracts were screened by two of the authors (MGG, CU), and
full-text copies of all potentially relevant studies were obtained.
Additional studies were identiﬁed from the reference lists of full-
text articles, and reviewed for potential inclusion.Eligibility criteria
Published full-text studies that evaluated reirradiation of rectal
or rectosigmoid cancer were considered for inclusion. Studies of
patients with locally recurrent rectal cancer were eligible if they
included patients previously irradiated for rectal cancer and if they
reported outcomes after additional external beam radiotherapy
with or without concomitant chemotherapy. Prospective, retro-
spective, and randomised controlled trials were eligible. Case
reports and reviews were excluded. Studies evaluating external
beam reirradiation combined with other radiation techniques such
as stereotactic body radiotherapy (SBRT) or intraoperative
radiotherapy (IORT) were not included. Eligibility was assessed
independently by three of the authors (MGG, CU, BLR), and ﬁnal
inclusion in the review was based on consensus.364 records screened 
11 addi
lists of 
353 titles/abstracts from 
literature search 
10 publications eligible and 
included in systematic review 
316
48 full-text publications 
assessed for eligibility
Fig. 1. Search strategy and inclusEvaluation of studies
The three authors assessed quality of the full-text papers inde-
pendently, before consensus was obtained. Evaluation criteria
focused on external validity and included the relevance of the
patient population, the homogeneity of the patients and treat-
ments, and the appropriateness of the methods used, based on a
revised scoring system from the Norwegian Knowledge Centre
for the Health Services.
Data regarding patient characteristics, previous radiotherapy,
reirradiation details, and outcomes were extracted from the stud-
ies independently by the three authors and presented in tables.
Consensus was obtained on the data extracted, and data presenta-
tion and interpretation (all authors). A meta-analysis was not fea-
sible due to heterogeneity of studies and outcomes.Endpoints of interest
For patients treated with curative intent, the effects of reirradi-
ation in terms of R0 resection rate, survival, and acute and late tox-
icity were evaluated. For patients treated with palliative intent, the
effects of reirradiation on symptom palliation, survival, toxicity,
and HRQOL were evaluated. The clinical implications of reirradia-
tion in terms of total dose, target volume, and fractionation regi-
mens, and possible recommendations for clinical practice, were
discussed.
Results
The search resulted in 331 titles/abstracts; the updated yielded
an additional 22, and 11 from reference lists, leading to a total of
364 titles/abstracts (Fig. 1). These titles/abstracts were screened,
and 48 full-text publications were reviewed. Ten publications
describing seven patient cohorts/studies met the inclusion criteria
and were included in the ﬁnal analysis [16–25].
There were no randomised controlled studies; all studies were
prospective or retrospective (Table 1). A total of 375 patients
treated with reirradiation (range 13–103) were included. The stud-
ies published up to 2006 included patients with locally recurrent
rectal cancer without distant metastases. Later studies also
included patients previously irradiated for other pelvic cancers
[22,25]; and in the study by Ng et al., 40% of patients had meta-
static disease [25]. The median age ranged from 50 to 69 years,tional from reference 
publications 
38 non-eligible and excluded due to: 
- abstract only (2) 
- combination other radiotherapy modalities (12) 
- combination hyperthermia (3) 
- not results of reirradiation (14) 
- reviews on recurrence (7) 
 records excluded 
ion of publications in review.
Table 1
Study characteristics, patient characteristics, and details of previous radiotherapy in the included studies.
Author and Publication
year
Study design and Inclusion
period
Reirradiated
N
Patient population Age
median,
years
(range)
Previous RT dose
median, Gy
(range)
Time since RT
median, months
(range)
Ng 2013 [25] Retrospective 1997–2008 56 RC, previous pelvic RTb
Curative n = 13, Palliative
n = 43
69 (26–88) 50.4 Gy (21–64) 30 (8–176)
Sun 2012 [24] Prospective 2004–2008 72 Recurrent irresectable RC 59 (29–78) <50 Gy (NR) 25 (13–77)
Koom 2012 [23] Retrospective 2000–2007 22 Recurrent RC 50 (33–64) 54 Gy (45–59.4) 26 (5–72)
Das 2010 [22] Retrospective 2001–2005 50 RC, previous pelvic RTc
Primary n = 2, Recurrent
n = 48
60 (32–80) 47 Gy (25–70) 28 (5–354)
Valentini 2006 [21] Prospective phase II 1997–
2001
59 Recurrent RC
No extrapelvic disease
62 (43–77) 50.4 Gy (30–55) 27 (9–106)
Mohiuddin 2002 [19] NRa 1987–2000 103 Recurrent RC 65 (31–79) 50.4 Gy (30–74) 19 (2–86)
Valentini 1999 [20] Prospective 1989–1997 13
(subgroup)
Recurrent RC
No metastases
NR NR (27–59) NR
Lingareddy 1997 [18] NRa 1987–1993 52 Recurrent RC
Palliative n = 52
65 (37–79) 50.4 Gy (40–70.2) 24 (3–86)
Mohiuddin 1997 [17] NRa 1987–1992 39 Recurrent RC
Curative n = 39
61 (31–77) 50.4 Gy (40–45)
boost up to 66
18 (3–456)
Mohiuddin 1993 [16] Phase I/II pilot 1987–1991 32 Recurrent RC
Curative n = 17, Palliative
n = 15
60 (31–79) 45 Gy (30–66) Curative: 8 (3–456)
Palliative: 27 (3–79)
NR = not reported in original publication; RC = rectal cancer; RT = radiotherapy.
a Reirradiation program.
b Previous RT for other cancer (7%); prostate n = 3, endometrial n = 1.
c Previous RT for other cancer (14%); cervical n = 2, prostate n = 2, bladder n = 1.
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vious RT dose was mostly 50.4 Gy, previous fractionation regimen
was rarely described, but assumed to be 1.8–2.0 Gy per fraction.
The median time since previous RT varied from 8 to 30 months.
Reirradiation doses and techniques are summarised in Table 2,
and estimates of the EQD2Gy doses in Supplementary Table. An evo-
lution of reirradiation over time was demonstrated. In the early
series reported by Mohiuddin et al., reirradiation was administered
with either 1.2 Gy twice daily or 1.8 Gy daily to approximately
30 Gy, followed by a boost of 6–20 Gy [16–19]. The median reirra-
diation dose given was 30.6–36 Gy, delivered by opposed lateral
ﬁelds or three-ﬁeld technique, encompassing the presacral region
and gross tumour volume (GTV) with 2–4 cm margins, and com-
bined to concomitant 5-ﬂuorouracil (5-FU) continuous infusion.
In the prospective study of patients with recurrent rectal cancer
reported by Valentini et al., 1.2 Gy twice daily with concomitant
5-FU was given to the GTV plus a 4-cm margin to a total dose of
30 Gy; thereafter, additional CRT to a total of 40.8 Gy was given
to GTV plus 2-cm margin [21]. Das et al. reported on patients
who received 1.5 Gy twice daily and concomitant 5-FU. Patients
with a long interval since previous treatment (P1 year) received
a total dose of 39 Gy, and patients with shorter intervals 30 Gy
[22]. The treatment was delivered to GTV with a 2–3 cm margin,
mostly by three-ﬁeld technique.
Koom et al. reported on a smaller series of patients treated more
heterogeneously with 1.8–3.0 Gy once daily, to a median reirradi-
ation dose of 50.2 Gy, with techniques including conformal RT,
intensity-modulated radiation therapy (IMRT), and tomotherapy
[23]. Sun et al. reported on patients treated with 1.2 Gy twice daily
to a reirradiation dose of 30–36 Gy delivered by 5–8 ﬁelds deliv-
ered to GTV plus 2 cm, with concomitant capecitabine [24]. In
non-resectable patients, the GTV was redrawn and RT continued
to a total dose of 51.6–56.4 Gy, thus delivering a high reirradiation
dose to patients with irresectable local recurrence.
Finally, Ng et al. reported on patients with rectal cancer who
had had previous pelvic radiotherapy, of whom 40% had metastatic
disease. They were treated with 1.8 Gy once daily to a reirradiation
dose of 39.6 Gy, with concomitant 5-FU. The treatment volumeincluded GTV plus a 2-cm margin; most patients were treated by
three-ﬁeld technique and some with IMRT [25].
To summarise the treatment given, reirradiation for rectal can-
cer was mostly given with hyperfractionated chemoradiotherapy
to total doses of 30–40 Gy, although higher doses have been
explored. Once-daily reirradiation was mostly used for palliative
intent. The treatment volumes encompassed the tumour with mar-
gins, in newer studies delivered by multiple ﬁelds.
The median follow-up time ranged from 15 to 36 months
(Table 3). R0 resection was obtained in 39–89% of patients who
underwent tumour resection; the wide range probably reﬂecting
differences in patient selection. Further local recurrence occurred
in approximately 50% of resected patients. The median survival
ranged from 39 to 60 months in resected patients and from 12 to
16 months in palliative patients.
A high proportion of patients reirradiated with palliative intent
to median doses ofP30 Gy obtained symptomatic relief (Table 3).
The proportion with complete or partial pain relief ranged from
83% to 94%. Rectal bleeding resolved completely in 100% of
patients. The majority (>80%) of patients experienced partial or
complete symptom relief from gastrointestinal symptoms or rectal
mass. The median duration of symptom relief was 8 months for
mass effect, 9 months for pain, and 10 months for bleeding [18,19].
The rate of treatment interruption or termination due to toxic-
ity was >30% in the earlier studies by Mohiuddin et al. (Table 4)
[16–19] and was later reduced to 13% [20] and 4% [24,25]. This
reduction in acute toxicity seems to be correlated with increasingly
conformal radiotherapy and smaller margins to the GTV, and
possibly better selection. The most commonly observed grade
3–4 toxicities were diarrhoea and skin reactions (Table 4), the
frequency were reduced in the later studies.
Late toxicity was not prospectively evaluated probably because
most studies were retrospective, follow-up was relatively short,
and patients treated with palliative intent had limited life
expectancy. The most commonly reported late toxicities were
gastrointestinal and urinary complications such as small bowel
obstruction, ﬁstula, stricture, chronic diarrhoea, and cystitis
(Table 4). Factors that inﬂuenced the development of late toxicity
Table 2
Reirradiaton treatment.
Author and
Year
Planned RT regimen
fraction dose/total dose
Reirradiation
dose
median
(range)
Treatment volume Technique Cumulative
dose
median
(range)
Concomitant
chemotherapy
Ng 2013 [25] 1.8 Gy/39.6 Gy 39.6 Gy
(20–39.6)
GTV
CTV = GTV + 1 cm
PTV = CTV + 1 cm
3DCRT 2–4 ﬁelds or
IMRT
87.3 Gy
(44.4–108)
5-FU
Sun 2012 [24] 1.2 Gy bid/30–36 Gy (n = 18)
Non-resectable:
redraw GTV, total 51.6–56.4 Gy
(n = 54)
GTV
CTV = GTV + 1 cm
PTV = CTV + 1 cm
3DCRT 5–8 ﬁelds NR Capecitabine
Koom 2012 [23] 1.8–3 Gy/NR 50.2 Gy
(30–66)
GTV + 2–3 cm 3DCRT or IMRT or
tomotherapy
103.3 Gy
(81–119.4)
Yes
Das 2010 [22] 1.5 Gy bid/30–39 Gya 39 Gy (94%)
30 Gy (6%)
GTV + 2–3 cm 3-ﬁeld NR Capecitabine
Valentini 2006 [21] 1.2 Gy bid/30 Gy (PTV2)
+1.2 Gy bid/10.8 Gy (PTV1)
40.8 Gy GTV + 4 cm (PTV2)
GTV + 2 cm (PTV1)
3DCRT NR 5-FU
Mohiuddin 2002 [19] 1.2 Gy bid/30 Gy + boost
6–20 Gyb (n = 43)
or
1.8 Gy/30.6 Gy + boost 6–20 Gy
(n = 60)
34.8 Gy
(15–49.2)
Presacral region and
GTV + 2–4 cm
Boost: GTV + 2 cm
2 lateral ﬁelds or
3-ﬁeld
85.8 Gy
(70.6–108)
5-FU
Valentini 1999 [20] 1.8 Gy/23.4 Gy 23.4 Gy GTV + 1.5 cm
+ posterior pelvis
Box or 3-ﬁeld NR 5-FU/MMC
Lingareddy 1997 [18] 1.2 Gy bid/30 Gy + boost
6–20 Gy (n = 22)
or
1.8 Gy/30.6 Gy + boost 6–20 Gy (n = 30)
30.6 Gy
(19.8–40.8)
Presacral region and
GTV + 2–3 cm
Boost: GTV + 62 cm
2 lateral ﬁelds 84.4 Gy
(66.6–104.9)
5-FU
Mohiuddin 1997 [17] 1.2 Gy bid/30 Gy + boost
6–20 Gyc (n = 21)
or
1.8 Gy/30.6 Gy + boost 6–20 Gyc (n = 18)
36 Gy
(19.8–49.2)
Presacral region and
GTV + min 2 cm
Boost: limited tumour
volumes
2 lateral ﬁelds 85.7 Gy
(70.6–99.8)
5-FU
Mohiuddin 1993 [16] Curative:
1.2 Gy bid/30 Gy ± boost 10 Gy (n = 17)
Palliative:
1.8 Gy/30 Gy ± boost 10 Gy (n = 15)
34.2 Gy
(19.8–47.7)
Posterior half pelvis
Boost GTV + <2 cm
2 lateral ﬁelds NR
(70.6–111.6)
5-FU
Bid: two fractions daily; GTV: gross tumour volume; CTV: clinical target volume; PTV: planning target volume; 3-ﬁeld: 1 posterior and 2 lateral ﬁelds.
3DCRT: 3-dimensional conformal radiotherapy; IMRT: intensity-modulated radiotherapy; 5-FU: 5-ﬂuorouracil; MMC: Mitomycin C; NR: not reported.
a Total dose 39 Gy if time since previous RTP 1 year, 30 Gy if time since previous RT < 1 year.
b Higher boost dose if >1 year interval from initial RT.
c Boost if >1 year from initial RT.
Table 3
Treatment results after reirradiation. Radical surgery and survival after reirradiation. Symptom palliation in non-resected patients.a
Author
year
Follow-up
median, months
(range)
Surgery
tumour resection,
n (%)
Survivalb
median, months
Symptom palliation,
n (%)
All Resected Palliative
Ng 2013 [25] 15 (1–108) Surgery 12/56 (21%) 19 39 15 Overall RR 88%, CR 24/49 (49%) PR 19/49 (39%)
Resection 11/56 (20%) Rectal bleeding/discharge 100%
R0: 8 GI CR 50% PR 50%
Pain CR 47% PR 44%
Urinary CR 1/1 (100%)
Vaginal bleeding CR 2/3 (67 %)
Sun 2012 [24] 24 (10–57) Resection 18/72 (25%) 32 – – Pain relief 29/31 (94%)
R0: 16 Tenesmus relief 23/28 (82%)
Koom 2012 [23] 20 (7–91) Resection 5/22 (23%) 21 – –
Das 2010 [22] 25 (0–71) Resection 18/50 (36%) 26 60 16
R0: 7
Valentini 2006 [21] 36 (9–69) Resection 30/59 (51%) 42 – – Pain relief 20/24 (83%)
R0: 21
Mohiuddin 2002 [19] 24 (3–84) Surgery 41/103 (40%) 26 44 14 Bleeding CR 21/21 (100%)
Resection 34/103 (33%) Pain CR 25/46 (54%) PR 13/46 (28%)
Mass effect CR 9/36 (25%) PR 23/36 (64%)
Valentini 1999 [20] NR Resection 4/13 (31%) – – –
Lingareddy 1997 [18] 16 NA – – 12
Mohiuddin 1997 [17] 36 (24–77) Resection 31/39 (79%) – 45
R0: 27
Mohiuddin 1993 [16] NR (12–72) Surgery 17/32 (53%) – – 14
Resection 15/32 (49%)
Operated: number of patients operated; Reirradiated: number of patients reirradiated.
R0: number of patients with microscopic radical resection; NR: not reported; RR: response rate; CR: complete response; PR: partial response.
a Data from selected studies where palliation was reported, and median reirradiation dose wasP30 Gy. The publications by Mohiuddin et al. [16] and Lingareddy et al. [18]
also reported on symptom palliation, but these patients are included in the publication by Mohiuddin et al. [19].
b Survival: either median survival or overall survival was reported.
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Table 4
Acute and late toxicity after reirradiation.
Author
year
Acute toxicitya grade 3
or 4
Treatment break or
termination (toxicity)
Late toxicity, n
Ng 2013 [25] Skin 5%
Gastrointestinal 9%
Mucositis 2%
Termination 4% Infection/abscess/drainage/discharge 4/12, ﬁstula 1/12, urinary infection/retention 2/12,
small bowel obstruction 1/12, delayed wound healing 1/12, skin ulceration 1/43
Sun 2012 [24] Diarrhoea 10%
Granulocytopenia 8%
Termination 4% Skin ﬁbrosis 4/72, urinary incontinence/dysuria 4/72, small bowel obstruction 1/72
Koom 2012 [23] Diarrhoea 9% – Grade 3–4 toxicity 8/22 – small bowel obstruction, ﬁstula, urinary stricture, haematologic
Das 2010 [22] Nausea/vomiting 4% – Grade 3 toxicity 12/50 – small bowel obstruction, wound complication, abscess, ﬁstula,
ureteral stricture/leakage, haemorrhage, joint disease, nausea
Grade 4 toxicity 1/50 – cystitis
Valentini 2006 [21] Gastrointestinal 5% Break 10%
Termination 3%
Skin ﬁbrosis 2/59, impotence 2/59, urinary incontinence/dysuria 2/59, small bowel
obstruction 1/59
Mohiuddin 2002 [19] Diarrhoea 20%
Moist desquamation
8%
Mucositis 4%
Break 22%
Termination 15%
Diarrhoea 8/103, small bowel obstruction 15/103, ﬁstula (recurrence) 4/103, skin
ulceration 2/103
Valentini 1999 [20] Haematologic/
diarrhoea 8% (same
patient)
–
Lingareddy 1997 [18] Diarrhoea 19%
Perineal skin
breakdown 8%
Mucositis 4%
Break/termination
31%
Small bowel obstruction 9/52, cystitis 3/52, ﬁstula 4/52, skin ulceration 1/52
Mohiuddin 1997 [17] Diarrhoea 13%
Moist desquamation
10%
Mucositis 5%
Delayed wound
healing 6%
Break 18%
Termination 13%
Chronic diarrhoea 3/39, small bowel obstruction 6/39, ﬁstula (recurrence) 3/39, coloanal
stricture 2/6
Mohiuddin 1993 [16] Diarrhoea 13%
Skin reaction 13%
Pelvic abscess 6%
– Delayed wound healing 2/17, small bowel obstruction 1/17, coloanal stricture 1/5
a Toxicity scored by Common Toxicity Criteria (CTC) or RTOG score.
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between initial radiotherapy and reirradiation [19], tumour loca-
tion within the pelvis [23], and fractionation regimen [19]. None
of the studies evaluated health-related HRQOL.Discussion
This systematic review of reirradiation for patients with locally
recurrent rectal cancer revealed that reirradiation is feasible and
has acceptable acute toxicity, although there is limited evidence
on late toxicity. Reirradiation was delivered as hyperfractionated
or once-daily regimens to total doses of 30–40 Gy to the GTV with
2–4 cm margins, and concurrent chemotherapy. The aims of the
treatment were to achieve a curative resection with radical sur-
gery, or to obtain tumour control and symptom palliation.
Radical surgery is the main predictor for increased survival
[11,26]. Thus, an aggressive multimodal and surgical approach is
justiﬁed if R0 resection may be possible. Surgery of local recur-
rence is challenging, since the normal anatomical boundaries and
surgical planes have been distorted and previous radiotherapy
may have induced ﬁbrosis, and because recurrence often involves
other pelvic organs or structures [11]. Reirradiation may downsize
the tumour and increase the chance of an R0 resection [26],
although it is not clear whether all patients beneﬁt from reirradia-
tion. Patients who underwent tumour resection experienced a
longer median survival than patients with inoperable disease
[19,21,22,25], however more toxicity was reported in patients
who underwent surgery [23,25]. It was difﬁcult to know whether
late toxicity was due to radiotherapy, surgery, or symptoms from
further recurrence. Future studies are needed to deﬁne the optimal
curative treatment for previously irradiated patients with recur-
rent rectal cancer.The distinction between curative and palliative intent is often
not clear, and in several studies reviewed this depended on
whether patients were eligible for curative resection after reirradi-
ation. Patients reirradiated with palliative intent had a shorter
median survival, but reported good symptom palliation of bleed-
ing, pain, and gastrointestinal symptoms [16,18,19,21,24,25]. This
is in line with a recent review of palliative radiotherapy for rectal
cancer, reporting good symptomatic relief [27], and a review
reporting efﬁcacy of reirradiation for bone metastases [28]. The
need for symptom palliation and the expected beneﬁts of reirradi-
ation must be weighed against the expected survival.
The main organs at risk are the small bowel and the bladder.
Clinical evidence concerning reirradiation tolerance is lacking
[29], and dose constraints are not given. For small bowel, there
are suggestions for constraints in the literature to minimise acute
toxicity [30], and experimental evidence suggests consequential
chronic damage; however, a correlation with late toxicity has not
been established. For bladder, experimental studies suggest no late
toxicity recovery, and a strong consequential component [14], but
reliable tolerance data are not known. Surgery following reirradia-
tion is often extensive and may result in colostomy and urostomy.
Furthermore, complications such as perforation, obstruction,
bleeding, incontinence, and ﬁstula are also associated with persis-
tent or recurrent disease [19,22]. Reirradiation should be given to
limited volumes using small margins and highly conformal ther-
apy, thereby reducing small bowel and bladder doses [14,30].
HRQOL was not reported in any of the reirradiation studies, but
in disease-free patients after radiotherapy and surgery for recur-
rent rectal cancer, acceptable HRQOL has been described even after
pelvic exenteration [31,32]. On the other hand, signiﬁcant deterio-
ration occurs in patients with progressive disease [10]. Future trials
should address patient-reported outcomes and HRQOL after reirra-
diation for recurrent rectal cancer.
156 Reirradiation of rectal recurrenceMost studies included in this review used hyperfractionated
radiotherapy, administered in 1.2–1.5 Gy fractions twice daily, at
least for curative treatment [16–22,24]. Once-daily fractions of
1.8 Gy were mostly an option for palliative treatment or patient
preference [16–19,23,25]. The fractionation regimens were proba-
bly chosen due to radiobiological rationale, extrapolation from
other tumour sites, and feasibility. Although several studies used
different regimens, patients were not randomised, making compar-
ison between schedules difﬁcult.
The rationale for hyperfractionated, accelerated therapy is that
small fraction doses increases the therapeutic ratio by exploiting
the difference in fractionation sensitivity between tumour (high
a/b) and late-reacting normal tissue (low a/b) [33]. Reirradiation
doses can be recalculated to equivalent doses delivered with 2 Gy
fractions (EQD2Gy) for comparison of fractionation schemes
(EQD2Gy = n * d * ((d + a/b)/(2 + a/b))). A total dose of 39.6 Gy deliv-
ered with 1.2 Gy/fraction gives EQD2Gy = 33.3 Gy for late-reacting
tissue (a/b = 3 Gy), and a higher EQD2Gy = 37.0 Gy for tumour
(a/b = 10 Gy), assuming adequate time between the fractions to
allow normal tissue recovery. Repair half-times for human small
bowel are not certain, but assuming an incomplete repair factor
of 0.063 based on animal models [14], normal tissue has full
recovery by 6 h.
Hyperfractionated reirradiation should theoretically be the pre-
ferred treatment for patients with curative intent. It may also be
considered in patients with inoperable tumour with a relatively
long life expectancy, with the aim of durable local control. Although
some patients withmetastatic disease have long survival with com-
bination chemotherapy, many patients with disseminated disease
or poor performance status have a short life expectancy, and the
risk of late effects is less relevant. For these patients, once-daily
reirradiation has been shown to be feasible and effective [12,25]
and should in our opinion be considered the preferred treatment
regimen, considering convenience and patient preference.
Although treatment techniques have become more sophisti-
cated with time, the treatment principles remained the same. In
earlier studies, computed tomography (CT) was probably not used
for treatment planning; the target volume was the gross tumour
with margins of 2–4 cm and the presacral space, given by opposed
lateral ﬁelds to spare the anteriorly situated small bowel [16–20].
In recent studies, the GTV was delineated and margins of 1 cm to
the clinical target volume (CTV) and 1 cm to the planning target
volume (PTV) were added [21–25]. Treatment was delivered by
conformal radiotherapy or IMRT [23,25], in order to deliver high
tumour doses with acceptable small intestine and bladder doses.
There was a trend towards less acute and late toxicity in the recent
studies, probably due to better conformal treatment.
The total dose administered was mostly at the level of 30–
40 Gy; however, some studies administered a higher dose to a
smaller volume, depending on time elapsed since previous radio-
therapy [19] or in inoperable patients [24]. One study showed that
reirradiation doses >50 Gy increased the inﬁeld progression-free
survival [23]. For patients with inoperable disease, it seems that
higher doses can be administered safely, especially with conformal
CRT or IMRT, provided sufﬁciently low normal tissue doses. Esca-
lated doses to 51.6–56.4 Gy (hyperfractionated, shrinking-ﬁeld
after 36 Gy) with 5–8 ﬁelds were administered in one study, with
dose limitation to the bladder of 30 Gy and to the small intestine
10 Gy for <50% of volume [24]. A short time interval since previous
radiotherapy may result in worse radiation tolerance [19,22].
Modern imaging (i.e., magnetic resonance imaging and positron
emission tomography) and radiotherapy techniques (e.g., confor-
mal RT and IMRT) permit more precise target delineation, accurate
dose distribution, and narrow margins (e.g., cone beam CT and
image-guided radiotherapy), increasing accuracy and allowing for
individualised treatment.Reirradiation has been combined with IORT, where high radia-
tion doses are delivered to the tumour bed while organs at risk
are displaced or shielded from the radiation ﬁeld. Large retrospec-
tive institutional series from experienced centres have been pub-
lished in which subgroups received reirradiation to 30–30.6 Gy
followed by resection and IORT [26,34–36]. Good local control
and survival was shown, and results after reirradiation were as
good as after conventional preoperative irradiation [36]. Reirradia-
tion has been combined with hyperthermia [37,38] and has also
been delivered with brachytherapy [39] in patient series. SBRT
for reirradiation poses an interesting possibility for delivering high
doses to restricted volumes with very tight margins [40], although
there are limited data for recurrent rectal cancer, SBRT has been
used for presacral or pelvic wall recurrences [41,42].
Tumour classiﬁcation according to the site of recurrence within
the pelvis or according to degree of ﬁxation, determined by
preoperative imaging [11,43,44], may be helpful for decisions in
the multidisciplinary team (MDT) conference. Axial tumours were
most often resectable, in contrast with lateral or posterior
tumours; however, more toxicity was observed, probably due to
higher small bowel and bladder doses [23]. Presacral recurrence
had the worst prognosis and anastomotic recurrence the most
favourable prognosis [45]. Patients with higher ﬁxation grades
had worse outcomes [46]. A recent review of curative treatment
of locally recurrent rectal cancer emphasised the importance of
careful patient selection and optimised multimodality treatment
[47]. Patients should ideally be treated by experienced clinicians
in specialist centres [48].
Future trials should aim at prospective assessment of tumour
and normal tissue doses, investigate the optimal fractionation reg-
imen, and the acute and late toxicity including patient-reported
outcomes and HRQOL. Central review of CTV delineation in rectal
cancer may increase the CTV uniformity, and can be used for qual-
ity assurance for radiation treatment [49,50]. Methods for stand-
ardised data collection in rectal cancer has been described as a
tool to aid personalised medicine [51].
In summary, although treatment of previously irradiated
patients with recurrent rectal cancer is a challenge, several studies
have shown that reirradiation is feasible, safe, and effective in
terms of achieving radical resection or palliation. Retreatment is
likely to be even safer with modern staging and radiotherapy tech-
niques, allowing for increased accuracy and individualised radio-
therapy. Patients should undergo adequate diagnosis and MDT
discussion in experienced centres, and ideally be included in
prospective trials. When the intent is curative treatment, patients
should undergo hyperfractionated chemoradiotherapy followed
by radical surgery. If the intent is clearly palliative and life
expectancy is short, patients are probably best treated by once-
daily chemoradiotherapy.Conﬂict of interest statement
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